Research Topics
| C J McDougleSummaryAffiliation: Indiana University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Neurochemistry in the pathophysiology of autismChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202 4800, USA
J Clin Psychiatry 66:9-18. 2005..As these efforts move forward, it will be important to begin to integrate genetic studies with those involving neuroimaging and postmortem research in each of these 3 areas, as well as with pharmacologic treatment approaches...- Possible role of neuropeptides in obsessive compulsive disorderC J McDougle
Indiana University School of Medicine, Department of Psychiatry, Indianapolis 46202, USA
Psychoneuroendocrinology 24:1-24. 1999.... - Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidoneC J McDougle
University School of Medicine, Indianapolis, Indiana, USA
Child Adolesc Psychiatr Clin N Am 9:201-24. 2000..The design of this study and the assessments used are described separately... - A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorderC J McDougle
Department of Psychiatry, Section of Child and Adolescent Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202 5200, USA
Arch Gen Psychiatry 57:794-801. 2000..This report describes the first controlled study of risperidone addition in patients with OCD refractory to treatment with SRI alone... - Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitorsC J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, USA
J Autism Dev Disord 30:427-35. 2000..One controlled study of the selective SRI fluvoxamine found it to be significantly better than placebo for reducing repetitive phenomena and aggression in adults with autistic disorder. Additional research is needed... - Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disordersChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202 4800, USA
J Clin Psychiatry 69:15-20. 2008..Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed... - Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacologyChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202 4800, USA
Am J Psychiatry 162:1142-8. 2005..The authors report on whether risperidone improves the core symptoms of autism, social and communication impairment and repetitive and stereotyped behavior... - A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disordersC J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis 46202 5200, USA
Arch Gen Psychiatry 55:633-41. 1998..Open-label reports suggest that the serotonin2A-dopamine D2 antagonist risperidone may be safe and effective in reducing the interfering symptoms of patients with autism... - A retrospective analysis of quetiapine in the treatment of pervasive developmental disordersAdam H Corson
Department of Psychiatry, Indiana University School of Medicine and Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, Ind. 46202-4800, USA
J Clin Psychiatry 65:1531-6. 2004..CONCLUSION: Quetiapine was modestly effective for maladaptive behavior in patients with a PDD. Controlled studies are needed to further assess these preliminary findings... - Treatment of aggression in children and adolescents with autism and conduct disorderChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA
J Clin Psychiatry 64:16-25. 2003.... - Limited efficacy of ketoconazole in treatment-refractory major depressionR T Malison
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA
J Clin Psychopharmacol 19:466-70. 1999..These findings suggest a limited efficacy for ketoconazole in patients with treatment-refractory major depression... - A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disordersD J Posey
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, USA
J Child Adolesc Psychopharmacol 11:267-77. 2001..CONCLUSIONS: Mirtazapine was well tolerated but showed only modest effectiveness for treating the associated symptoms of autistic disorder and other PDDs... 
Pharmacotherapy of irritability in pervasive developmental disordersKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202 5200, USA
Child Adolesc Psychiatr Clin N Am 17:739-52, vii-viii. 2008..Additional large-scale, placebo-controlled studies of other medications are needed to determine their efficacy for the treatment of irritability in this diagnostic group...- Case series: use of ziprasidone for maladaptive symptoms in youths with autismChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis 46202-4800, USA
J Am Acad Child Adolesc Psychiatry 41:921-7. 2002..Significant weight gain was not observed in this short-term trial. Double-blind, placebo-controlled studies are needed to substantiate these preliminary findings... - A retrospective study of memantine in children and adolescents with pervasive developmental disordersCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
Psychopharmacology (Berl) 191:141-7. 2007..There are no drugs that have been shown to effectively treat the core social impairment of autism... - Pharmacotherapeutic management of autismD J Posey
Department of Psychiatry, Indaiana University School of Medicine, USA
Expert Opin Pharmacother 2:587-600. 2001..Current pharmacological management is best aimed at target symptoms that have been demonstrated to respond to medication in treatment studies... - Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disordersDavid J Posey
Department of Psychiatry and Christian Sarkine Autism Treatment Center at the Indiana University School of Medicine, Indianapolis, Indiana, USA
J Child Adolesc Psychopharmacol 16:599-610. 2006..The aim of this study was to conduct an initial evaluation of the efficacy of atomoxetine for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with pervasive developmental disorders (PDDs)... - The use of selective serotonin reuptake inhibitors in autism and related disordersDavid J Posey
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
J Child Adolesc Psychopharmacol 16:181-6. 2006..Larger, placebo-controlled studies of SSRIs are needed to guide clinical treatment... - Risperidone in pervasive developmental disordersCraig A Erickson
Riley Hospital, Child and Adolescent Psychiatry Clinic, 702 Barnhill Drive, ROC 4300, Indianapolis, IN 46202, USA
Expert Rev Neurother 5:713-9. 2005..Finally, a discussion of the future direction of risperidone use in this population and key issues will be presented... - Serotoninergic mechanisms in the treatment of obsessive-compulsive disorderAndrew W Goddard
Department of Psychiatry, Indiana University School of Medicine, University Hospital, UH3124, 550 North University Boulevard, Indianapolis, IN 46202, United States
Drug Discov Today 13:325-32. 2008..However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects... - Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorderKelda H Walsh
Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202, USA
Expert Opin Pharmacother 5:2059-67. 2004..Future investigations should include more controlled studies and investigate medications that are less likely to trigger extrapyramidal symptoms, diabetes mellitus and weight gain... - Ramelteon for insomnia in two youths with autistic disorderKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine and the Christian Sarkine Autism Treatment Center at the James Whitcomb Riley Hospital for Children, Indianapolis, Indiana 46202 5200, USA
J Child Adolesc Psychopharmacol 16:631-6. 2006..The aim of this study was to report preliminary data on the effectiveness and tolerability of ramelteon for the treatment of insomnia in youth with autistic disorder (autism)... 
Aripiprazole in autism spectrum disorders and fragile X syndromeCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
Neurotherapeutics 7:258-63. 2010..However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome...- Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measuresDavid J Posey
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA
Biol Psychiatry 61:538-44. 2007.... - Guanfacine and guanfacine extended release: treatment for ADHD and related disordersDavid J Posey
Christian Sarkine Autism Treatment Center, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
CNS Drug Rev 13:465-74. 2007..Adverse cardiovascular effects are uncommon, although modest reductions in blood pressure and heart rate are common. If GXR is FDA-approved, it would be the first alpha(2A) adrenoceptor agonist marketed for ADHD... - Brief report: acamprosate in fragile X syndromeCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, 702 Barnhill Drive, Room 4300, Indianapolis, IN 46202, USA
J Autism Dev Disord 40:1412-6. 2010..Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism... - Developing drugs for core social and communication impairment in autismDavid J Posey
Department of Psychiatry, Indiana University School of Medicine, 1111 West 10th Street, Indianapolis, IN 46202 4800, USA
Child Adolesc Psychiatr Clin N Am 17:787-801, viii-ix. 2008..More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms... - Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label studyKimberly A Stigler
Department of Psychiatry, Section of Child and Adolescent Psychiatry, Indiana University School of Medicine and Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana 46202 5200, USA
J Child Adolesc Psychopharmacol 19:265-74. 2009..The aim of this study was to determine the effectiveness and tolerability of aripiprazole for irritability in pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger's disorder... - Antipsychotics in the treatment of autismDavid J Posey
Christian Sarkine Autism Treatment Center, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
J Clin Invest 118:6-14. 2008..Significant adverse effects, including weight gain and the possibility of tardive dyskinesia, are reviewed. Future research directions are discussed... - Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 casesDavid J Posey
Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, 702 Barnhill Drive, Indianapolis, IN 46202 5200, USA
J Child Adolesc Psychopharmacol 14:233-41. 2004.... - Risperidone: a potential treatment for autismDavid J Posey
Riley Hospital for Children, Indianapolis, IN 46202, USA
Curr Opin Investig Drugs 3:1212-6. 2002..Individuals with autism may also have other symptoms that become the primary focus of psychiatric treatment. These associated symptoms include aggression, self-injury, irritability and anxiety... - Genetics of childhood disorders: XLIV. autism, part 3: psychopharmacology of autismChristopher J McDougle
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA
J Am Acad Child Adolesc Psychiatry 41:1380-3. 2002 - The pathophysiology and treatment of autismD J Posey
Department of Psychiatry, Indiana University School of Medicine, 541 Clinical Drive, Indianapolis, IN 46202, USA
Curr Psychiatry Rep 3:101-8. 2001..Significant gains have been made in determining which pharmacologic treatments are efficacious in autism. Additional research is needed on agents that might ameliorate the core and associated symptoms of autism... - A pilot study of D-cycloserine in subjects with autistic disorderDavid J Posey
Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46220, USA
Am J Psychiatry 161:2115-7. 2004..CONCLUSIONS: In this pilot study, D-cycloserine treatment resulted in significant improvement in social withdrawal. Further controlled studies of D-cycloserine in autism appear warranted... - Aripiprazole for maladaptive behavior in pervasive developmental disordersKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine and the James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202, USA
J Child Adolesc Psychopharmacol 14:455-63. 2004..No significant adverse effects emerged during these short-term trials. Additional research is needed to support these preliminary findings... - Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritabilityL Eugene Arnold
Department of Psychiatry, Ohio State University, Columbus, Ohio, USA
J Child Adolesc Psychopharmacol 20:83-93. 2010..2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder. This paper explores moderators and mediators of this effect... - Pharmacological strategies for trichotillomaniaKelda H Walsh
Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202, USA
Expert Opin Pharmacother 6:975-84. 2005..For other patients, other antidepressants, neuroleptics or even topical agents may be helpful. Future investigations should include more controlled studies and longer observation for relapse... - Intramuscular ziprasidone for acute agitation in adolescentsEmmeline Hazaray
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA
J Child Adolesc Psychopharmacol 14:464-70. 2004..In our study, we report the cases of 3 youngsters whose escalating aggression responded to intramuscular ziprasidone with an immediate calming effect and good clinical outcome... - Trichotillomania. Presentation, etiology, diagnosis and therapyK H Walsh
Indiana University School of Medicine, Indianapolis, Indiana, USA
Am J Clin Dermatol 2:327-33. 2001..Specialized psychotherapy, known as habit reversal training, is highly recommended; however, the treatment is intensive and highly specialized. Skilled therapists are difficult to locate... - Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and managementKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202-4800, USA
Paediatr Drugs 6:33-44. 2004.... - Pharmacologic treatment of autism and related disordersCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, and the Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis 46202-4800, USA
Pediatr Ann 36:575-85. 2007 - Increased prevalence of familial autoimmunity in probands with pervasive developmental disordersThayne L Sweeten
Department of Psychiatry, Indiana University School of Medicine, and James Whitcomb Riley Hospital for Children Indianapolis 46202-4800, USA
Pediatrics 112:e420. 2003..These preliminary findings warrant additional investigation into immune and autoimmune mechanisms in autism... - Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disordersGerard J Marek
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
Neuropsychopharmacology 28:402-12. 2003.... - From anxiety to autism: spectrum of abnormal social behaviors modeled by progressive disruption of inhibitory neuronal function in the basolateral amygdala in Wistar ratsWilliam A Truitt
Department of Psychiatry, Indiana University School of Medicine, 1111 West 10th Street, Indianapolis, IN 4620, USA
Psychopharmacology (Berl) 191:107-18. 2007..Social behaviors are disrupted in several psychiatric disorders. The amygdala is a key brain region involved in social behaviors, and amygdala pathology has been implicated in disease states ranging from social anxiety disorder to autism... - Ziprasidone treatment of two adolescents with psychosisKaren G Meighen
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, USA
J Child Adolesc Psychopharmacol 14:137-42. 2004..These patients presented with hallucinations and grossly disorganized speech and behavior. Further study is needed to determine if these findings can be generalized... - Pharmacological management of agitation and aggression in an adolescent with autismChristopher J Kratochvil
Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198, USA
J Am Acad Child Adolesc Psychiatry 44:829-32. 2005 - Emerging drugs for the treatment of symptoms associated with autism spectrum disordersLogan K Wink
Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN 46202, USA
Expert Opin Emerg Drugs 15:481-94. 2010..The use of pharmacologic agents in the treatment of these disorders can reduce the impact of interfering symptoms, providing relief for affected individuals and their families... - A naturalistic retrospective analysis of psychostimulants in pervasive developmental disordersKimberly A Stigler
Department of Psychiatry, Indiana University School of Medicine, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana, USA
J Child Adolesc Psychopharmacol 14:49-56. 2004..Response may differ with PDD subtype. Controlled studies are needed to further evaluate these preliminary findings in a systematic manner... - Tolerability profile of atypical antipsychotics in children and adolescentsK A Stigler
Department of Psychiatry, Indiana University School of Medicine, 541 Clinical Drive, Indianapolis, IN 46202-5111, USA
Paediatr Drugs 3:927-42. 2001..Lack of evidence for bodyweight gain with ziprasidone is a considerable advantage... - Acute onset of obsessive-compulsive disorder in an adolescent with acute lymphoblastic leukemiaDouglas R Morris
Section of Child and Adolescent Psychiatry, Department of Psychiatry, Indiana University School of Medicine, Bloomington, IN, USA
Psychosomatics 46:458-60. 2005 - Brief report: autistic disorder in three children with cytomegalovirus infectionThayne L Sweeten
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202-4800, USA
J Autism Dev Disord 34:583-6. 2004..A better understanding of the immunologic response to certain congenital infections may provide important information pertaining to the pathophysiology and etiology of autism in vulnerable individuals... - High blood monocyte counts and neopterin levels in children with autistic disorderThayne L Sweeten
Department of Psychiatry, Indiana University School of Medicine, 1111 West 10th Street, Indianapolis, IN 46202-4800, USA
Am J Psychiatry 160:1691-3. 2003..RESULTS: The monocyte count and neopterin level were significantly higher in the autistic children than in the comparison subjects. CONCLUSIONS: These results suggest that the immune system may be activated in some children with autism... - Gastrointestinal factors in autistic disorder: a critical reviewCraig A Erickson
Department of Psychiatry, Indiana University School of Medicine, Indianapolis 46202-4800, USA
J Autism Dev Disord 35:713-27. 2005..While much literature is available on this topic, a dearth of rigorous study was found to validate GI factors specific to children with autism... - Serotonin and dopamine transporter binding in children with autismChristopher J McDougle
Dept. of Psychiatry, Indiana University School of Medicine, USA
Dev Med Child Neurol 50:565. 2008 - High nitric oxide production in autistic disorder: a possible role for interferon-gammaThayne L Sweeten
Department of Psychiatry, Indiana University School of Medicine, 1111 W. 10th Street, Indianapolis, IN 46202-4800, USA
Biol Psychiatry 55:434-7. 2004..51; p =.005). CONCLUSIONS: These results confirm that plasma NO is high in some children with autism and suggest that this elevation may be related to IFN-gamma activity... - The amygdala and related structures in the pathophysiology of autismThayne L Sweeten
Department of Psychiatry, Indiana University School of Medicine, 541 Clinical Drive, Room 298, Indianapolis, IN 46202-5111, USA
Pharmacol Biochem Behav 71:449-55. 2002..Although supportive evidence exists for amygdala dysfunction in autism, the currently available data are inconsistent and additional research is needed... - Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot studyRonald L Lindsay
Children s Health Center of St Joseph s Hospital and Medical Center, Arizona 85013, USA
J Intellect Dev Disabil 31:204-9. 2006..Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain... - Acute tryptophan depletion in schizophrenic patients treated with clozapineTony P George
Arch Gen Psychiatry 59:291-2. 2002 - Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioningDenis G Sukhodolsky
The Child Study Center, Yale University, 230 South Frontage Road, New Haven, CT 06520, USA
J Abnorm Child Psychol 36:117-28. 2008..Limited data are available on the prevalence of anxiety in these children. We examined frequency and correlates of parent-rated anxiety symptoms in a large sample of children with PDD... - Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective dataAndres Martin
Yale Child Study Center, Yale University, New Haven, CT 06520, USA
Am J Psychiatry 161:1125-7. 2004..The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change... - Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disordersLawrence Scahill
Yale Child Study Center, Yale University, New Haven, CT 06520, USA
J Am Acad Child Adolesc Psychiatry 45:1114-23. 2006..To examine the psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scales (CYBOCS) modified for pervasive developmental disorders (PDDs)... - Assessment of the integrity of study blindness in a pediatric clinical trial of risperidoneBenedetto Vitiello
Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Clin Psychopharmacol 25:565-9. 2005..The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism... - Risperidone and adaptive behavior in children with autismSusan K Williams
Yale University, New Haven, CT 06520-7900, USA
J Am Acad Child Adolesc Psychiatry 45:431-9. 2006..Vineland age-equivalent scores appear to be most useful in assessing change with treatment over time... - Effects of short- and long-term risperidone treatment on prolactin levels in children with autismGeorge M Anderson
Child Study Center, Yale University School of Medicine, New Haven, Connecticut, USA
Biol Psychiatry 61:545-50. 2007..The effects of short- and long-term risperidone treatment on serum prolactin were assessed in children and adolescents with autism... - Risperidone in children with autism and serious behavioral problemsJames T McCracken
University of California, Los Angeles, USA
N Engl J Med 347:314-21. 2002..The short period of this trial limits inferences about adverse effects such as tardive dyskinesia... - A prospective open trial of guanfacine in children with pervasive developmental disordersLawrence Scahill
Yale Child Study Center, P O Box 207900, New Haven, CT 06520, USA
J Child Adolesc Psychopharmacol 16:589-98. 2006..A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with PDD and hyperactivity... - Methylphenidate an effective treatment for ADHD?Christopher J McDougle
J Autism Dev Disord 34:593-4. 2004 - Research knowledge among parents of children participating in a randomized clinical trialBenedetto Vitiello
Child and Adolescent Treatment and Preventive Intervention Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9633, USA
J Am Acad Child Adolesc Psychiatry 44:145-9. 2005..Parental permission is required for child research, but parents' understanding of research aims and procedures has not been well documented. Parental research knowledge was assessed during a clinical trial in autism... - Acute and long-term safety and tolerability of risperidone in children with autismMichael G Aman
The Nisonger Center, Ohio State University, Columbus, Ohio 43210 1296, USA
J Child Adolesc Psychopharmacol 15:869-84. 2005..Most AEs were mild to moderate and failed to interfere with therapeutic changes; there were no unanticipated AEs. The side effects of most concern were somnolence and weight gain... - Obsessive-compulsive disorder (OCD)Christopher J McDougle
J Autism Dev Disord 35:685-6. 2005 - Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adultsAudrey R Tyrka
Department of Psychiatry and Human Behavior, Brown Medical School, Providence, Rhode Island, USA
Biol Psychiatry 56:531-4. 2004..This study examined the effect of tryptophan depletion, which acutely reduces brain serotonin concentrations, on serial cerebrospinal fluid concentrations of corticotropin-releasing factor in healthy humans... - Priapism associated with trazodone in an adolescent with autismDeborah L Kem
J Am Acad Child Adolesc Psychiatry 41:758. 2002 - Validity of the autism diagnostic interview-revisedLuc Lecavalier
Nisonger Center, The Ohio State University, Columbus, USA
Am J Ment Retard 111:199-215. 2006..They indicated some similarities between constructs, but also that the ADI-R measures autism in a unique fashion... - Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disordersChristopher J McDougle
Psychopharmacology (Berl) 191:1-3. 2007 - Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomaniaLinda L Carpenter
Mood Disorders Research Program, Butler Hospital, and Department of Psychiatry and Human Behavior, Brown Medical School, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA
Psychiatry Res 112:257-62. 2002..3+/-0.8 pg/ml) and their matched controls (n=14) (1.9+/-0.5 pg/ml). These findings fail to support speculation that ongoing immune activation may be causally involved in the pathogenesis of OCD or trichotillomania... - Developmental disabilities modification of the Children's Global Assessment ScaleAnn Wagner
National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
Biol Psychiatry 61:504-11. 2007..To measure global functioning in treatment studies, the Children's Global Assessment Scale was modified and psychometric properties of the revised version (DD-CGAS) were assessed in children with PDD...
Research Grants
- RUPP-PIChristopher McDougle; Fiscal Year: 2006..The RUPP-PI at Indiana University is also prepared to participate in treatment studies involving children and adolescents with other psychiatric disorders. ..
- Novel Pharmacological Strategies in AutismChristopher McDougle; Fiscal Year: 2009..Phase II (following 6 months of aripiprazole monotherapy). ..
- 1/4-RUPP Autism Network: Guanfacine for the Treatment of Hyperactivity in PDDChristopher J McDougle; Fiscal Year: 2010..Methylphenidate or placebo will be added for children who show partial benefit to guanfacine. ..